key: cord-0843781-122ofx5c
authors: Brailovsky, Yevgeniy; Masoumi, Amirali; Bijou, Rachel; Oliveros, Estefania; Sayer, Gabriel; Takeda, Koji; Uriel, Nir
title: Fulminant Giant Cell Myocarditis Requiring Bridge With Mechanical Circulatory Support to Heart Transplantation
date: 2022-03-02
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2021.11.013
sha: 24a66e13f3a5df3113cf0be362a479ac4f9bcde2
doc_id: 843781
cord_uid: 122ofx5c

Giant cell myocarditis is a rare cause of cardiogenic shock requiring a high index of suspicion, rapid immunosuppressive therapy, and mechanical circulatory support. We present the case of a patient with giant cell myocarditis who underwent a successful bridge with four different types of mechanical circulatory support devices to heart transplantation. (Level of Difficulty: Advanced.)

G iant cell myocarditis (GCM) is a rare cause of cardiogenic shock requiring a high index of suspicion, rapid immunosuppressive therapy, and mechanical circulatory support. We present the case of a patient with GCM based on clinical pre-sentation, who had a delay in pathologic diagnosis amid the COVID-19 pandemic, but eventually underwent successful bridge with four different types of mechanical circulatory support devices to orthotopic heart transplantation (OHT).

Our patient is a 69-year-old woman with nonischemic dilated cardiomyopathy and a left ventricular ejection fraction (LVEF) of 35%, who recovered her LVEF with guideline-directed medical therapy and cardiac resynchronization therapy. She now presented with 1 week of fever, chills, diarrhea, and worsening dyspnea. There were signs and symptoms of shock and end-organ hypoperfusion.

To recognize giant cell myocarditis as a cause of cardiogenic shock resulting from biventricular heart failure and ventricular arrhythmias. To engage the multidisciplinary team in the decision pathways for escalation of mechanical circulatory support to preserve endorgan function and improve survival. However, the presentation can vary in severity, and maintaining a high clinical suspicion is imperative to establishing a correct diagnosis. An early endomyocardial biopsy can establish the diagnosis and lead to the implementation of therapy. 1, 2 Endomyocardial biopsy is limited by sampling error and lacks the sensitivity to definitively rule out GCM, as occurred in our patient. 3 Considering a worsening cardiovascular status and with positive viral titers, there was a high suspicion for myocarditis. Therefore, our patient underwent a cardiac biopsy on hospital day 12 and was treated with empiric high-dose steroids with 1 g methylprednisolone. The endomyocardial biopsy results were nondiagnostic. our case, their patient was significantly older and was not a candidate for OHT or durable VAD. The patient was successfully treated with antithymocyte globulin and pulse-dose intravenous methylprednisolone, and underwent transition away from mechanical circulatory support and was discharged with maintenance immunosuppression. 7 

The authors have reported that they have no relationships relevant to the contents of this paper to disclose. 

Giant cell myocarditis in an older patient: reassessing the threshold for endomyocardial biopsy

Management of patients with giant cell myocarditis: JACC review topic of the week

Diagnosis, treatment, and outcome of giantpredominantly of lymphocytes, numerous mononuclear cells, scattered eosinophils, and multinucleate giant cells. Extensive healing fibrosis, which appears to be approximately 2 weeks old. immunosuppression

Usefulness of immunosuppression for giant cell myocarditis

Fulminant giant-cell myocarditis on mechanical circulatory support: management and outcomes of a French multicentre cohort

Outcomes of mechanical circulatory support for giant cell myocarditis: a systematic review

Biventricular intravascular microaxial blood pumps and immunosuppression as a bridge to recovery in giant cell myocarditis

Management of a patient presenting with giant cell myocarditis: a case report

A giant mystery in giant cell myocarditis: navigating diagnosis, immunosuppression, and mechanical circulatory support

KEY WORDS cardiac transplant, acute heart failure